Physician profile
Whitney Hunter
NPI 1164842514
$3,086.85
in general payments reported to CMS, 2019-2025
21 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 96% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $728 · 2024: $1,098 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $551.91 | 2023-2025 | Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $429.96 | 2022-2025 | Keytruda, Lynparza, Rotateq |
| Daiichi Sankyo INC. | $346.57 | 2023-2025 | Enhertu, Vanflyta |
| Genmab U.S., INC. | $295.96 | 2022-2025 | Tivdak |
| Abbvie INC. | $233.45 | 2025 | |
| Stemline Therapeutics INC. | $176.50 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $148.66 | 2023-2025 | Phesgo, Itovebi, Perjeta |
| Astellas Pharma US INC | $148.41 | 2024-2025 | Veozah |
| Immunogen, INC. | $146.55 | 2023 | Elahere |
| Lilly USA, LLC | $135.39 | 2023-2025 | Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $117.21 | 2023 | Jemperli |
| Seagen INC. | $88.52 | 2023 | Tukysa |
| Tersera Therapeutics LLC | $70.52 | 2024-2025 | Zoladex |
| Myriad Genetic Laboratories, INC. | $61.44 | 2023-2024 | Myrisk |
| Eisai INC. | $31.09 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $21.40 | 2022 | |
| Incyte Corporation | $21.17 | 2025 | Jakafi |
| Caris Mpi, INC. | $18.36 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $14.67 | 2024 | |
| Gilead Sciences, INC. | $14.66 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.